BioCentury
ARTICLE | Clinical News

Esperion reports first Phase III hypercholesterolemia data

March 8, 2018 12:08 AM UTC

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily oral bempedoic acid (ETC-1002) met the primary endpoint in the Phase III CLEAR Tranquility (1002-048) trial to treat hypercholesterolemia in patients with atherosclerotic cardiovascular disease (ASCVD). The company also reported that two patients in the bempedoic acid arm had liver enzyme elevations that were more than three times the upper limit of normal.

Esperion's stock fluctuated throughout the day on the news, losing $7.93 (10%) to $70.01 in midday trading Wednesday, and ending the day off $1.65 to $76.29...

BCIQ Company Profiles

Esperion Therapeutics Inc.

BCIQ Target Profiles

ATP citrate lyase